Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials
Journal of Clinical Oncology, 01/03/08

De Laurentiis M et al. - In a study to evaluate the efficacy, disease-free survival (DFS), and overall survival (OS) after incorporating taxanes into anthracycline-based regimens for early breast cancer (EBC), it was found that the addition of a taxane improves the DFS and OS of high-risk EBC patients

Methods

Studies were retrieved by searching the PubMed database and the proceedings of major conferences
Hazard ratios (HR) and 95% CIs were extracted for DFS and OS from each trial and pooled estimates were obtained using an inverse-variance model

Results

13 studies were included in the meta-analysis of 22,903 patients
The pooled HR estimate was 0.83 for DFS and 0.85 for OS
Risk reduction was not influenced by the type of taxane, by estrogen receptor (ER) expression, by number of axillary metastases, or by patient's age/menopausal status
Sensitivity analysis showed that taxanes given in combination with anthracyclines did not significantly improve OS
The test for interaction showed that HR did not differ between the 2 schedules
Taxane administration resulted in an absolute 5-year risk reduction of 5% for DFS and 3% for OS

<< Previous
Infrastructure: Right price

Next >>
Determination of the specific activity of CDK1 and CDK2 as a...